4//SEC Filing
Meyer Robert J. 4
Accession 0001209191-21-056051
CIK 0001693415other
Filed
Sep 13, 8:00 PM ET
Accepted
Sep 14, 7:27 PM ET
Size
13.5 KB
Accession
0001209191-21-056051
Insider Transaction Report
Form 4
Meyer Robert J.
Director
Transactions
- Sale
Stock Option (right to buy)
2021-09-14−20,000→ 0 totalExercise: $20.43Exp: 2031-06-15→ Common Stock (20,000 underlying) - Sale
Stock Option (right to buy)
2021-09-14−37,800→ 0 totalExercise: $7.49Exp: 2029-01-01→ Common Stock (37,800 underlying) - Sale
Stock Option (right to buy)
2021-09-14−18,900→ 0 totalExercise: $10.20Exp: 2029-06-17→ Common Stock (18,900 underlying) - Sale
Stock Option (right to buy)
2021-09-14−18,900→ 0 totalExercise: $15.33Exp: 2030-06-15→ Common Stock (18,900 underlying)
Footnotes (5)
- [F1]As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.
- [F2]This option was granted on June 18, 2019. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2020.
- [F3]This option was granted on January 2, 2019. The shares underlying this option are scheduled to vest and become exercisable in equal monthly installments, beginning on February 2, 2019 and ending on the three year anniversary of January 2, 2019.
- [F4]This option was granted on June 16, 2020. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2021.
- [F5]This option was granted on June 16, 2021. This option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant.
Documents
Issuer
Translate Bio, Inc.
CIK 0001693415
Entity typeother
Related Parties
1- filerCIK 0001735298
Filing Metadata
- Form type
- 4
- Filed
- Sep 13, 8:00 PM ET
- Accepted
- Sep 14, 7:27 PM ET
- Size
- 13.5 KB